The award is a phase II Small Business Innovation Research grant from the U.S. National Institutes of Aging. Of the total funds, $1 million for the first year has been authorized. The remainder is contingent upon approval of an interim report and availability of funds.
ADM said it is using brain imaging, artificial intelligence, and blood biomarkers to develop
analysis tools that can be used by clinicians to assess and differentiate brain effects in early, potentially reversible stages. This also includes when and if chronic traumatic encephalopathy may be progressing.
Copyright © 2022 AuntMinnie.com